Skip to main content

Storage, Expression and Function of Fas Ligand, the Key Death Factor of Immune Cells

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

The TNF family member Fas ligand (FasL) induces apoptosis in Fas-expressing cells and serves as a key death factor in the immune system. It is involved in the termination of immune responses by activation-induced cell death, the selection of thymocytes and T and NK cell-mediated cytotoxicity. FasL also participates in the establishment of immune privilege and contributes to tumor cell survival. Besides its death-inducing capacity, FasL has been implicated in retrograde signal transduction into FasL expressing cells by socalled “reverse signalling”. In this context, FasL may also act as an accessory/costimulatory molecule. Dysregulation within the Fas/FasL-system manifests in a severe impairment of the functional integrity and maintenance of immune homeostasis. As its receptor Fas is abundantly expressed in several tissues, the expression of FasL has to be tightly regulated to prevent unwanted damage. At the post-transcriptional level, this is achieved by several independent mechanisms, for example the safe intracellular storage, an activationdependent mobilization, the association with lipid rafts and the shedding by metalloproteases. Of interest, the intracellular portion of FasL contains a unique proline-rich domain, which plays a major role in the control of FasL transport and expression due to interactions with proteins containing SH3 or WW interaction domains. The detailed analysis of FasL-interacting proteins and their functional characterization provided novel insights into the complex processes regulating FasL expression and signal transduction. This knowledge should allow to improve Fas/FasL-based therapeutical approaches that are currently under development.

Keywords: Fas ligand; Nck; PCH protein family; TNF family; activation-induced cell death; apoptosis; reverse signalling; secretory lysosome

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986708784872384

Affiliations: Institute of Immunology, UK S-H Campus Kiel, Michaelisstr. 5, 24105 Kiel, Germany.

Publication date: July 1, 2008

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
ben/cmc/2008/00000015/00000017/art00003
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more